查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938784

狂犬病診斷市場－全球產業規模、佔有率、趨勢、機會及預測（依診斷方法、技術、地區及競爭格局分類，2021-2031年）

Rabies Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnostic Method, By Technology Method, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球狂犬病診斷市場預計將從 2025 年的 27.8 億美元成長到 2031 年的 44.6 億美元，複合年成長率為 8.20%。

此細分市場包括體外診斷研究調查方法，例如直接螢光抗體檢測 (DFA)、聚合酵素鏈鎖反應(PCR) 和酵素免疫分析法(ELISA)，這些方法用於檢測人類和動物檢體中的通用病毒。市場擴張的主要原因是感染疾病發病率的上升以及旨在消除犬源性狂犬病的「同一健康」計劃的加強。此外，寵物主人數量的增加以及政府對動物疫苗接種和跨境運輸的嚴格監管也推動了對快速、準確診斷工具的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 27.8億美元
市場規模：2031年 44.6億美元
複合年成長率：2026-2031年 8.2%
成長最快的細分市場 螢光抗體技術（FAT）
最大的市場 北美洲

市場發展的主要障礙在於先進診斷技術成本高昂，以及開發中國家（疾病負擔最重）缺乏檢測基礎設施。這種不公平現象限制了資源匱乏地區廣泛採用先進檢測通訊協定。根據美國獸醫協會 (AVMA) 2024 年的報告，在上一個監測期內，美國提交了約 89,530 份動物檢體進行狂犬病檢測。這些數據凸顯了持續監測的重要性，同時也顯示新興市場的資金限制仍限制全球取得這些關鍵診斷資源。

市場促進因素

旨在2030年消除狂犬病的國際策略舉措正在透過確保資金投入和優先開展地方性流行地區的監測工作，顯著改變狂犬病的診斷格局。國際組織正在加速將狂犬病控制納入更全面的衛生投資框架，為永續的市場成長奠定基礎。作為這項轉變的象徵，世界衛生組織（世衛組織）於2024年6月宣布，全球疫苗免疫舉措（Gavi）董事會已核准將用於暴露後免疫的人用狂犬病疫苗納入其投資策略。預計這項決定將系統性地改善目標國家的治療可近性，並需要改進診斷追蹤。這項策略調整旨在應對狂犬病帶來的巨大經濟影響。 2024年8月，美國農業部估計，光是在美國，狂犬病的檢測、預防和控制的年度總成本就將超過5億美元。

同時，分子診斷和側向流動診斷技術的進步，透過提供快速、經濟且適用於各種檢測環境的選擇，正在擴大市場進入。製造商正積極開發和推出基於免疫檢測的解決方案，以減少對複雜實驗室設備的依賴，從而提高獸醫和人類醫療保健領域的檢測效率。例如，2024年2月，百奧通動物保健公司宣布推出AsurDx狂犬病抗體檢測試劑盒，這是一款基於酶聯免疫吸附試驗（ELISA）的產品，旨在快速檢測哺乳動物血清中的狂犬病毒抗體。這些創新對於滿足日益成長的有效疫苗監測和疾病監測需求至關重要，並確保診斷能力與全球根除狂犬病的目標一致。

市場挑戰

先進診斷技術的高昂成本，加上開發中國家實驗室基礎設施的匱乏，是全球狂犬病診斷市場發展的主要障礙。聚合酵素鏈鎖反應(PCR) 和直接螢光抗體檢測 (DFA) 等先進技術靈敏度極高，但需要大量的設備、可靠的電力供應和專業人員投入。在狂犬病高發生率的資源匱乏地區，這些先決條件往往難以滿足，造成了經濟差距。這種差距有效地阻礙了可靠檢測套組的普及，迫使醫療系統依賴臨床觀察，而非購買診斷試劑盒。

因此，在理論上疾病負擔最重的地區，市場滲透十分困難，產生收入往往僅限於擁有成熟監測網路的已開發國家。未能進入高負擔國家會限制全球貿易，並阻礙製造商在新興經濟體拓展分銷網路。世界衛生組織（世衛組織）估計，到2024年，狂犬病造成的全球經濟負擔約為每年86億美元，這一數據凸顯了嚴重的財政限制，這些限制制約了這些地區衛生系統採購必要診斷設備的能力。

市場趨勢

為了支持精準的流行病學追蹤，市場越來越重視基因序列測定和變異分型，而非簡單的病毒存在/缺失檢測。實驗室正從傳統的直接螢光抗體（DFA）檢測轉向分子表徵，以識別特定的病毒譜系並監測跨物種傳播途徑。這一轉變使公共衛生官員能夠區分傳統型株和引入性變異株，這對於在非流行地區制定有針對性的干涉策略至關重要。根據美國獸醫協會（AVMA）於2025年7月發布的《2023年美國狂犬病監測報告》，35.6%的陽性檢體接受了病毒表徵以識別特定變異株，這表明疾病管理越來越依賴先進的分子技術。

一個值得關注的趨勢是擴大監測範圍，以捕捉對都市區和近郊居民構成持續威脅的野生動物宿主。與以往以家畜為中心的模式不同，這些擴展後的監測網路專注於監測特定的野生動物媒介，例如蝙蝠和狐狸，它們在犬類狂犬病已被控制的地區是主要的宿主。這種轉變需要將本地數據整合到更廣泛的國家追蹤系統中，以便及早發現疫情爆發。例如，根據加拿大動物健康監測系統於2025年2月發布的“狂犬病疫情最新情況”，2024年安大略省確診的蝙蝠傳播狂犬病病例數達到91例，這凸顯了持續開展野生動物監測對於防止狂犬病再次傳入家畜種群至關重要。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球狂犬病診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 透過診斷方法（螢光抗體試驗（FAT）、免疫組織化學、擴增法、組織學、血清學）
    • 依技術（ELISA/免疫組織化學、層析法技術、PCR 等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美狂犬病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲狂犬病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區狂犬病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲狂犬病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲狂犬病診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球狂犬病診斷市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bio-Rad Laboratories, Inc
  • Merck KGaA
  • Aviva Systems Biology Corporation.
  • Creative Diagnostics
  • Demeditec Diagnostics GmbH.
  • Abbexa Ltd.
  • Norgen Biotek Corp.
  • BioNote, Inc.
  • Express Biotech International Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19870

The Global Rabies Diagnostics Market is projected to increase from a valuation of USD 2.78 Billion in 2025 to USD 4.46 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.20%. This market segment includes in vitro diagnostic methodologies such as Direct Fluorescent Antibody (DFA) testing, Polymerase Chain Reaction (PCR), and Enzyme-Linked Immunosorbent Assays (ELISA), which are utilized to detect the rabies virus in specimens from both humans and animals. Market expansion is largely fueled by the rising incidence of zoonotic diseases and intensified "One Health" efforts aimed at eradicating dog-mediated rabies. Additionally, growing rates of pet ownership and the enforcement of strict government mandates regarding animal vaccination and cross-border transport are boosting the demand for fast and precise diagnostic tools.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.78 Billion
Market Size 2031USD 4.46 Billion
CAGR 2026-20318.2%
Fastest Growing SegmentFluorescent Antibody Test (FAT)
Largest MarketNorth America

A major obstacle hindering market progress is the prohibitive cost of advanced diagnostic technologies combined with the insufficiency of laboratory infrastructure in developing nations, where the burden of disease is most severe. This inequality restricts the broader application of sophisticated testing protocols in resource-limited areas. As reported by the American Veterinary Medical Association in 2024, approximately 89,530 animal specimens were submitted for rabies testing within the United States during the preceding surveillance interval. While such figures underscore the essential nature of consistent surveillance, financial limitations in emerging markets persist in limiting global access to these critical diagnostic resources.

Market Driver

Strategic international initiatives designed to achieve rabies elimination by 2030 are significantly transforming the diagnostics landscape by securing funding and prioritizing surveillance in endemic zones. Global organizations are increasingly incorporating rabies control into comprehensive healthcare investment frameworks, establishing a solid foundation for sustainable market growth. Highlighting this shift, the World Health Organization noted in June 2024 that the Gavi Board approved the addition of human rabies vaccines for post-exposure prophylaxis to its investment strategy, a decision anticipated to systematically enhance access to care and drive the need for improved diagnostic tracking in eligible nations. This strategic realignment targets the significant economic impact of the disease; the U.S. Department of Agriculture estimated in August 2024 that the aggregate annual costs for rabies detection, prevention, and control in the United States alone exceed $500 million.

Simultaneously, technological progress in molecular and lateral flow diagnostic assays is widening market access by providing fast, affordable options adaptable to various testing settings. Manufacturers are vigorously creating and releasing immunoassay-based solutions that decrease dependence on sophisticated laboratory setups, thereby boosting testing rates in both veterinary and human health sectors. For example, BioStone Animal Health reported in February 2024 the commercial release of the AsurDx Rabies Antibody Test Kit, an ELISA-based product engineered for the swift identification of rabies virus antibodies in mammalian serum. These innovations are essential to satisfy the increasing requirement for effective vaccine monitoring and disease surveillance, ensuring diagnostic capacities align with global elimination targets.

Market Challenge

The substantial expense associated with sophisticated diagnostic technologies, coupled with the scarcity of laboratory infrastructure in developing countries, presents a significant barrier to the growth of the Global Rabies Diagnostics Market. Although advanced techniques like Polymerase Chain Reaction (PCR) and Direct Fluorescent Antibody (DFA) testing provide superior sensitivity, they necessitate heavy capital expenditure on machinery, reliable power supplies, and specialized personnel. These prerequisites are frequently missing in low-resource areas where the disease is most endemic, creating an economic divide that effectively blocks the adoption of dependable testing kits and compels healthcare systems to rely on clinical observation rather than purchasing diagnostic solutions.

Consequently, the market struggles to penetrate regions that theoretically possess the highest patient volumes, thereby confining revenue generation primarily to developed nations with mature surveillance networks. This failure to secure a position in high-burden countries dampens global transaction volumes and discourages manufacturers from scaling distribution networks in emerging economies. According to the World Health Organization, the global economic burden of rabies was estimated at approximately US$ 8.6 billion annually in 2024, a statistic that underscores the profound financial restrictions limiting the ability of these health systems to fund essential diagnostic procurement.

Market Trends

The market is increasingly prioritizing genomic sequencing and variant typing over simple presence-absence detection to support precise epidemiological tracking. Laboratories are shifting from traditional Direct Fluorescent Antibody (DFA) testing toward molecular characterization to identify specific viral lineages and monitor cross-species transmission pathways. This evolution allows public health authorities to distinguish between indigenous and translocated variants, which is crucial for targeted intervention strategies in non-endemic zones. According to the American Veterinary Medical Association, July 2025, in the 'Rabies surveillance in the United States during 2023' report, 35.6% of all positive rabies samples underwent virus characterization to identify specific variants, underscoring the growing reliance on advanced molecular insights for disease management.

There is a distinct trend toward widening surveillance architectures to capture wildlife reservoirs that pose a persistent threat to urban and peri-urban populations. Unlike traditional models focused on domestic animals, these expanded networks focus on monitoring distinct wildlife vectors such as bats and foxes, which serve as primary reservoirs in regions where dog-mediated rabies is controlled. This shift necessitates the integration of regional data into broader national tracking systems to detect spillover events early. For instance, according to the Canadian Animal Health Surveillance System, February 2025, in the 'Status Update for Rabies' report, confirmed cases of bat variant rabies in Ontario reached 91 in 2024, highlighting the critical need for sustained wildlife monitoring to prevent reintroduction into domestic populations.

Key Market Players

  • Bio-Rad Laboratories, Inc
  • Merck KGaA
  • Aviva Systems Biology Corporation.
  • Creative Diagnostics
  • Demeditec Diagnostics GmbH.
  • Abbexa Ltd.
  • Norgen Biotek Corp.
  • BioNote, Inc.
  • Express Biotech International Inc.

Report Scope

In this report, the Global Rabies Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rabies Diagnostics Market, By Diagnostic Method

  • Fluorescent Antibody Test (FAT)
  • Immunohistochemical Test
  • Amplification Methods
  • Histologic Examination
  • Serology Tests

Rabies Diagnostics Market, By Technology Method

  • ELISA/Immunohistochemistry
  • Chromatography Techniques
  • PCR
  • Others

Rabies Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rabies Diagnostics Market.

Available Customizations:

Global Rabies Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rabies Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnostic Method (Fluorescent Antibody Test (FAT), Immunohistochemical Test, Amplification Methods, Histologic Examination, Serology Tests)
    • 5.2.2. By Technology Method (ELISA/Immunohistochemistry, Chromatography Techniques, PCR, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Rabies Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnostic Method
    • 6.2.2. By Technology Method
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rabies Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Diagnostic Method
        • 6.3.1.2.2. By Technology Method
    • 6.3.2. Canada Rabies Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Diagnostic Method
        • 6.3.2.2.2. By Technology Method
    • 6.3.3. Mexico Rabies Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Diagnostic Method
        • 6.3.3.2.2. By Technology Method

7. Europe Rabies Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnostic Method
    • 7.2.2. By Technology Method
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rabies Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnostic Method
        • 7.3.1.2.2. By Technology Method
    • 7.3.2. France Rabies Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnostic Method
        • 7.3.2.2.2. By Technology Method
    • 7.3.3. United Kingdom Rabies Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnostic Method
        • 7.3.3.2.2. By Technology Method
    • 7.3.4. Italy Rabies Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Diagnostic Method
        • 7.3.4.2.2. By Technology Method
    • 7.3.5. Spain Rabies Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Diagnostic Method
        • 7.3.5.2.2. By Technology Method

8. Asia Pacific Rabies Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnostic Method
    • 8.2.2. By Technology Method
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Rabies Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnostic Method
        • 8.3.1.2.2. By Technology Method
    • 8.3.2. India Rabies Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnostic Method
        • 8.3.2.2.2. By Technology Method
    • 8.3.3. Japan Rabies Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnostic Method
        • 8.3.3.2.2. By Technology Method
    • 8.3.4. South Korea Rabies Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Diagnostic Method
        • 8.3.4.2.2. By Technology Method
    • 8.3.5. Australia Rabies Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Diagnostic Method
        • 8.3.5.2.2. By Technology Method

9. Middle East & Africa Rabies Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnostic Method
    • 9.2.2. By Technology Method
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Rabies Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnostic Method
        • 9.3.1.2.2. By Technology Method
    • 9.3.2. UAE Rabies Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnostic Method
        • 9.3.2.2.2. By Technology Method
    • 9.3.3. South Africa Rabies Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnostic Method
        • 9.3.3.2.2. By Technology Method

10. South America Rabies Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnostic Method
    • 10.2.2. By Technology Method
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rabies Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Diagnostic Method
        • 10.3.1.2.2. By Technology Method
    • 10.3.2. Colombia Rabies Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Diagnostic Method
        • 10.3.2.2.2. By Technology Method
    • 10.3.3. Argentina Rabies Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Diagnostic Method
        • 10.3.3.2.2. By Technology Method

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Rabies Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bio-Rad Laboratories, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck KGaA
  • 15.3. Aviva Systems Biology Corporation.
  • 15.4. Creative Diagnostics
  • 15.5. Demeditec Diagnostics GmbH.
  • 15.6. Abbexa Ltd.
  • 15.7. Norgen Biotek Corp.
  • 15.8. BioNote, Inc.
  • 15.9. Express Biotech International Inc.

16. Strategic Recommendations

17. About Us & Disclaimer